BioCorRx Acquires LUCEMYRA, Sees Significant Revenue Growth in Q1 2025
TL;DR
BioCorRx Inc. acquired LUCEMYRA® (lofexidine), the FDA-Approved Opioid Withdrawal Medication, giving them a competitive edge in the substance abuse treatment market.
LUCEMYRA® is a non-opioid medication approved by the FDA to alleviate opioid withdrawal symptoms by reducing the release of norepinephrine.
BioCorRx's acquisition of LUCEMYRA® provides critical relief for patients undergoing opioid detoxification, improving the quality of life for individuals struggling with substance abuse.
Research funded by NIH to develop BICX104, a naltrexone implant for methamphetamine use disorder, offers hope for combating the growing public health challenge of MUD.
Found this article helpful?
Share it with your network and spread the knowledge!
BioCorRx Pharmaceuticals Inc. reported significant business developments in the first quarter of 2025, highlighted by the acquisition of LUCEMYRA®, an FDA-approved medication for managing opioid withdrawal symptoms. The strategic asset acquisition has already yielded notable financial results, with net product revenues increasing dramatically from $3,620 in the first quarter of 2024 to $134,899 in the same period of 2025.
The company continues to focus on innovative treatments for substance use disorders, maintaining a commitment to reducing operating expenses while exploring promising therapeutic interventions. Concurrent with the LUCEMYRA acquisition, BioCorRx is advancing research on BICX104, a subcutaneous naltrexone implantable pellet targeting methamphetamine use disorder (MUD).
The development of BICX104 is supported by a significant grant from the National Institutes of Health's National Institute on Drug Abuse. This research is particularly critical given the lack of approved medications for MUD and the expanding demographic at risk of methamphetamine-related overdose deaths.
CEO Lourdes Felix emphasized the strategic importance of the LUCEMYRA acquisition, noting that the medication represents a key revenue driver with potential to enhance shareholder value. The company's approach integrates pharmaceutical development with comprehensive treatment programs, including their Beat Addiction Recovery program and UnCraveRx® Weight Loss Program.
The acquisition and ongoing research underscore BioCorRx's commitment to addressing complex substance use disorders through innovative pharmaceutical and therapeutic approaches. By developing targeted interventions for opioid withdrawal, methamphetamine use, and related challenges, the company is positioning itself at the forefront of addiction treatment solutions.
Curated from NewMediaWire
